Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Greenleaf Trust

Greenleaf Trust raised its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 400.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 117,611 shares of the company's stock after purchasing an additional 94,113 shares during the period. Greenleaf Trust's holdings in Dr. Reddy's Laboratories were worth $1,857,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its position in Dr. Reddy's Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock worth $36,000 after acquiring an additional 137 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Dr. Reddy's Laboratories in the 3rd quarter worth approximately $60,000. Van ECK Associates Corp boosted its holdings in shares of Dr. Reddy's Laboratories by 64.3% during the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company's stock worth $64,000 after purchasing an additional 322 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Dr. Reddy's Laboratories by 83.2% in the third quarter. GAMMA Investing LLC now owns 1,447 shares of the company's stock valued at $115,000 after purchasing an additional 657 shares in the last quarter. Finally, Glenmede Trust Co. NA acquired a new stake in shares of Dr. Reddy's Laboratories in the third quarter valued at approximately $207,000. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 1.8 %

RDY stock traded up $0.25 during midday trading on Tuesday, hitting $13.86. 1,460,430 shares of the company's stock were exchanged, compared to its average volume of 2,067,747. Dr. Reddy's Laboratories Limited has a 1-year low of $13.36 and a 1-year high of $16.89. The business has a 50-day simple moving average of $14.79 and a two-hundred day simple moving average of $15.41. The stock has a market capitalization of $11.57 billion, a PE ratio of 22.07 and a beta of 0.50. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Barclays lowered their price objective on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 6th. Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th. Finally, StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.